Stryker (NYSE:SYK) Releases FY 2026 Earnings Guidance

Stryker (NYSE:SYK) updated its FY 2026 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of 14.900-15.100 for the period, compared to the consensus estimate of 14.960. The company issued revenue guidance of -.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on SYK. Citigroup reissued a “market outperform” rating on shares of Stryker in a report on Friday. UBS Group set a $408.00 target price on Stryker in a research note on Monday, October 13th. Robert W. Baird set a $437.00 price target on Stryker in a research note on Friday. Truist Financial dropped their price objective on Stryker from $400.00 to $392.00 and set a “hold” rating on the stock in a report on Thursday, December 18th. Finally, Needham & Company LLC raised their target price on Stryker from $448.00 to $454.00 and gave the company a “buy” rating in a report on Friday. Twelve equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $426.95.

Stryker Stock Performance

SYK opened at $369.39 on Friday. Stryker has a 1-year low of $329.16 and a 1-year high of $404.87. The stock has a market cap of $141.26 billion, a P/E ratio of 43.97, a P/E/G ratio of 2.27 and a beta of 0.89. The stock’s 50 day simple moving average is $359.40 and its 200 day simple moving average is $371.66. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.85 and a quick ratio of 1.13.

Stryker (NYSE:SYK) last posted its earnings results on Thursday, January 29th. The medical technology company reported $4.47 EPS for the quarter, topping analysts’ consensus estimates of $4.40 by $0.07. The company had revenue of $7.17 billion for the quarter, compared to the consensus estimate of $7.12 billion. Stryker had a return on equity of 24.73% and a net margin of 12.92%.Stryker’s quarterly revenue was up 11.4% compared to the same quarter last year. During the same period in the previous year, the business earned $4.01 earnings per share. As a group, equities analysts anticipate that Stryker will post 13.47 EPS for the current fiscal year.

Stryker Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, January 30th. Shareholders of record on Wednesday, December 31st were issued a dividend of $0.88 per share. This is an increase from Stryker’s previous quarterly dividend of $0.84. The ex-dividend date was Wednesday, December 31st. This represents a $3.52 annualized dividend and a yield of 1.0%. Stryker’s payout ratio is 46.25%.

Insider Buying and Selling at Stryker

In related news, CAO William E. Berry, Jr. sold 1,953 shares of the company’s stock in a transaction that occurred on Friday, November 14th. The stock was sold at an average price of $365.49, for a total value of $713,801.97. Following the sale, the chief accounting officer owned 2,833 shares of the company’s stock, valued at approximately $1,035,433.17. This represents a 40.81% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Preston Wendell Wells sold 165 shares of the stock in a transaction on Thursday, November 20th. The shares were sold at an average price of $365.88, for a total value of $60,370.20. Following the sale, the chief financial officer owned 6,694 shares in the company, valued at approximately $2,449,200.72. This trade represents a 2.41% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 522,118 shares of company stock valued at $185,381,932 over the last quarter. Corporate insiders own 5.90% of the company’s stock.

Trending Headlines about Stryker

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Q4 results beat estimates — adjusted EPS $4.47 vs. $4.40 consensus and revenue of $7.17B (organic growth ~11%), with management citing strong Mako adoption as a growth driver. SYK Stock Gains as Q4 Earnings & Sales Beat on Strong Mako Adoption
• Positive Sentiment: Company raised its full?year profit forecast and reported record revenue (>$25B FY2025) with adjusted operating margin expansion — supports upside to earnings expectations. Stryker raises annual profit forecast on strong sales for medical devices
• Positive Sentiment: Analysts are raising targets and reiterating buy ratings — Needham bumped its price target to $454 and reiterated Buy, reinforcing broker support after the print. SYK: Stryker price target raised by Needham Stryker: Sustained Double?Digit Growth and Operating Leverage Support Buy Rating
• Neutral Sentiment: 2026 guidance: management expects 8.0%–9.5% organic sales growth and adjusted EPS $14.90–$15.10 (roughly in line with street consensus); guidance shows continued growth but is narrowly ranged. Stryker projects 8%–9.5% organic sales growth for 2026
• Neutral Sentiment: Operating performance detail — adjusted operating margin widened ~100 bps to 30.2% in Q4 and management emphasizes margin expansion and new product launches as 2026 drivers. Stryker reports 2025 operating results and 2026 outlook
• Negative Sentiment: Headwinds and risks flagged — analysts and the company note possible 2026 tariff pressures, regulatory and macro risks that could constrain upside; keep an eye on cost/price dynamics and geopolitics. Stryker: Sustained Double?Digit Growth and Operating Leverage Support Buy Rating
• Negative Sentiment: Insider selling activity flagged in some data summaries — notable executive/insider sales were reported which some investors monitor as a negative signal (context and timing matter). Stryker Reports Strong Q4 and Full?Year 2025 Results (Quiver summary)

Institutional Trading of Stryker

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Brighton Jones LLC lifted its stake in shares of Stryker by 15.4% during the fourth quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock valued at $1,643,000 after buying an additional 609 shares during the period. Schnieders Capital Management LLC. acquired a new stake in shares of Stryker during the second quarter worth $205,000. Marshall Wace LLP grew its position in shares of Stryker by 107.9% in the second quarter. Marshall Wace LLP now owns 5,700 shares of the medical technology company’s stock valued at $2,255,000 after purchasing an additional 77,831 shares during the period. Nebula Research & Development LLC purchased a new stake in shares of Stryker in the second quarter valued at $219,000. Finally, HUB Investment Partners LLC acquired a new position in Stryker in the second quarter valued at $253,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.